S-OA-A Oral Abstracts - Session A - Allogeneic Transplants

Track: BMT Tandem "Scientific" Meeting
Wednesday, February 11, 2015: 4:45 PM-6:45 PM
Seaport Ballroom ABC (Manchester Grand Hyatt)
Chairs:
Richard E. Champlin, MD and Ephraim J. Fuchs, MD, MBA

Disclosures:
R. E. Champlin, Otsuka, Support: Research Funding

E. J. Fuchs, Nothing To Disclose

7
Moderate/Severe Grade of Chronic Graft Versus Host Disease and Younger Age (Less Than 45 Years Old) Are Risk Factors for Avascular Necrosis in Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Sita D Bhella, MD, Princess Margaret Cancer Center, University of Toronto; Jieun Uhm, MD, Princess Margaret Cancer Center, University of Toronto; Naheed Alam, MBBS, Princess Margaret Cancer Center, University of Toronto; Vikas Gupta, MD, Princess Margaret Cancer Center; John Kuruvilla, MD, Princess Margaret Cancer Center, University of Toronto; Jeffrey H Lipton, MD, PhD, Princess Margaret Cancer Center, University of Toronto; Hans Messner, MD, PhD, Princess Margaret Cancer Center, University of Toronto; Matthew Seftel, Princess Margaret Cancer Center, University of Toronto; Dennis (Dong Hwan) Kim, Princess Margaret Cancer Center, University of Toronto

8
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia
Hien K. Duong, MD, Cleveland Clinic; Mojtaba Akhtari, MD, University of Nebraska Medical Center; Kwang Woo Ahn, PhD, Medical College of Wisconsin; Zhen-Huan Hu, MS, Medical College of Wisconsin; Uday R. Popat, MD, UT MD Anderson Cancer Center; Edwin P. Alyea III, MD, Dana-Farber Cancer Institute; Richard T. Maziarz, MD, Oregon Health and Science University; Matt E. Kalaycio, MD, Cleveland Clinic; Wael Saber, MD, MS, Medical College of Wisconsin

17
Peripheral Blood Stem Cell Transplant in Aplastic Anemia
Pravas Chandra Mishra, MD, DM, All India Institute of Medical Sciences; Tulika Seth, MD, All India Institute of Medical Sciences; Manoranjan Mahapatra, MD, All India Institute of Medical Sciences

10
Administration of Plerixafor (a CXCR4 antagonist) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Enhances Platelet Recovery in a Phase I/II Trial
Michael M.B. Green, MD, Duke University Medical Center; Mitchell E. Horwitz, MD, Duke University Medical Center; Yubin Kang, MD, Duke University Medical Center; Nelson J. Chao, MD, MBA, Duke University Medical Center; Gwynn D Long, MD, Duke Univ Med Ctr BMT Prog; David Rizzieri, M.D., Duke Universtiy Medical Center; Cristina Gasparetto, MD, Duke University Medical Center; Anthony D. Sung, MD, Duke University Medical Center; Stefanie Sarantopoulos, MD, PhD, Duke University; Zhiguo Li, PhD, Duke University Medical Center; Kelly Corbet, Duke University; Emily Riggan-Stuelke, Duke University; Keith Sullivan, MD, Duke University Medical Center; Beth Wilson, Duke University; Saurabh Chhabra, MD, MUSC; Luciano V Costa, MD, *; Alice Mims, MUSC; Robert Stuart, MD, Medical University of South Carolina

11
Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-SCT) with Pre-Transplant Immunosuppression and Post-Transplant Cyclophosphamide (Post-Cy) in Severe Thalassemia: A Novel Approach Transplant for Nonmalignant Diseases
Suradej Hongeng, MD, Faculty of Medicine Ramathibodi hospital, Mahidol University; Samart Pakakasama, MD, Faculty of Medicine Ramathibodi hospital, Mahidol University; Usanarat Anurathapan, MD, Faculty of Medicine Ramathibodi hospital, Mahidol University; Borje S. Andersson, MD, PhD, UT M.D. Anderson Cancer Center

12
Prognostic Importance of Functional Capacity for Pre-Transplant Risk Assessment Among Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Lee W. Jones, PhD, Memorial Sloan Kettering Cancer Center; Sean Devlin, PhD, Memorial Sloan Kettering Cancer Center; Molly Malroy, Memorial Sloan Kettering Cancer Center; Noel Espiritu, Memorial Sloan Kettering Cancer Center; Jennifer Aquino, Memorial Sloan Kettering Cancer Center; Ceceile Hall, Memorial Sloan Kettering Cancer Center; William A. Wood, MD, MPH, University of North Carolina - Chapel Hill; Meghan Michalski, Memorial Sloan Kettering Cancer Center; Boglarka Gyurkocza, Memorial Sloan Kettering Cancer Center; Sergio A. Giralt, MD, Memorial Sloan-Kettering Cancer Center; Ann A. Jakubowski, PhD, MD, Memorial Sloan Kettering Cancer Center

13
Impact of Race on Graft-Versus-Host Disease Rates after HLA-Matched Sibling Bone Marrow or Peripheral Blood Hematopoietic Cell Transplantation: Comparison of North American Caucasian Versus Japanese Populations
Junya Kanda, MD, Saitama Medical Center, Jichi Medical University; Yachiyo Kuwatsuka, MD, PhD, Nagoya University Hospital; Ruta Brazauskas, PhD, Medical College of Wisconsin; Zhen-Huan Hu, MS, Medical College of Wisconsin; Koji Nagafuji, MD, PhD, Kurume University School of Medicine; Takahiro Fukuda, MD, PhD, National Cancer Center Hospital; Hisashi Sakamaki, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital; Carmem Bonfim, MD, Federal University of Paraná; Jignesh Dalal, MD, Children's Mercy Hospital; Theresa Hahn, PhD, Roswell Park Cancer Institute; Marcelo C. Pasquini, MD, MS, CIBMTR and Medical College of Wisconsin; Yoshiko Atsuta, MD, PhD, Nagoya University Graduate School of Medicine; Wael Saber, MD, MS, Medical College of Wisconsin

14
Extracorporeal Photophoresis in Reduced Intensity Conditioning: 14 Year Follow-up of 206 Patients Reveals an Efficacious Regimen with Low Rates of Gvhd
Esha Kaul, MD, Tufts Medical Center; Gunjan L. Shah, MD MS, Memorial Sloan-Kettering Cancer Center; Aaron Rosenberg, MD, UC Davis Medical Center; Raymond Comenzo, MD, Tufts Medical Center; Hedy Smith, MD PhD, Tufts Medical Center; Furha Cossor, MD MS, Lahey Hospital & Medical Center; Grace Kao, MD, Tufts Medical Center; Andrew Evens, DO, Tufts Medical Center; Kenneth B. Miller, MD, Tufts Medical Center; Andreas K Klein, MD, Tufts Medical Center; Kellie A Sprague, MD, Tufts Medical Center